{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "New York",
      "state": "NY",
      "country": "United States",
      "classification": "Class I",
      "openfda": {
        "application_number": [
          "NDA020699"
        ],
        "brand_name": [
          "EFFEXOR"
        ],
        "generic_name": [
          "VENLAFAXINE HYDROCHLORIDE"
        ],
        "manufacturer_name": [
          "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc."
        ],
        "product_ndc": [
          "0008-0836",
          "0008-0837",
          "0008-0833"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "VENLAFAXINE HYDROCHLORIDE"
        ],
        "rxcui": [
          "313581",
          "313583",
          "313585",
          "729929",
          "729931",
          "729932"
        ],
        "spl_id": [
          "3f8cf689-0fbb-4056-a85d-150dfd527313"
        ],
        "spl_set_id": [
          "53c3e7ac-1852-4d70-d2b6-4fca819acf26"
        ],
        "package_ndc": [
          "0008-0837-20",
          "0008-0837-21",
          "0008-0837-22",
          "0008-0837-02",
          "0008-0837-03",
          "0008-0833-20",
          "0008-0833-21",
          "0008-0833-22",
          "0008-0833-02",
          "0008-0833-03",
          "0008-0836-20",
          "0008-0836-21",
          "0008-0836-22",
          "0008-0836-02",
          "0008-0836-03"
        ],
        "is_original_packager": [
          true
        ],
        "unii": [
          "7D7RX5A8MO"
        ],
        "upc": [
          "300080836217",
          "300080836224"
        ]
      },
      "product_type": "Drugs",
      "event_id": "67636",
      "recalling_firm": "Pfizer Us Pharmaceutical Group",
      "address_1": "235 E 42nd St",
      "address_2": "N/A",
      "postal_code": "10017-5703",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",
      "distribution_pattern": "Nationwide and Puerto Rico",
      "recall_number": "D-1328-2014",
      "product_description": "Effexor XR (venlafaxine HCl) Extended-Release Capsules, 150 mg, packaged in a) 30-count Unit of Use bottles (NDC 0008-0836-21) UPC 3 0008-0836-21 7; b) 90-count Unit of Use bottles (NDC 0008-0836-22) UPC 3 0008-0836-22 4; Rx only, Distributed by Wyeth Pharmaceuticals Inc., A subsidiary of Pfizer Inc., Philadelphia, PA 19101.",
      "product_quantity": "49,847 bottles",
      "reason_for_recall": "Presence of Foreign Tablets/Capsules: A Pharmacist reported that a bottle of Effexor XR 150 mg capsules contained a single peach colored capsule printed TKN250 which was identified as a Tikosyn (dofetilide) capsule.",
      "recall_initiation_date": "20140306",
      "center_classification_date": "20140520",
      "termination_date": "20170510",
      "report_date": "20140528",
      "code_info": "Lot #: a) V130142, Exp 10/15; b) V130140, Exp 10/15"
    }
  ]
}